{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:39:37Z","timestamp":1793047177168,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with recurrent, chronic, or refractory cytopenias represent a challenging subgroup that may harbor an underlying diagnosis, such as an inborn error of immunity (IEI). Patients with IEIs such as activated phosphoinositide 3-kinase delta syndrome (APDS), frequently have hematologic manifestations, but these are not often reported as presenting symptoms. As a result, IEIs may be overlooked in patients presenting with early and\/or recalcitrant cytopenias. Here, we describe the diagnostic journey and management of three patients who presented to a pediatric hematologist\/oncologist with early-onset or recalcitrant cytopenias and were ultimately diagnosed with APDS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentations<\/jats:title><jats:p>Patients presented with early-onset and\/or refractory cytopenias, with two of the three developing multilineage cytopenias. Prior to an APDS diagnosis, two patients underwent a total of approximately 20 procedures, including biopsies, invasive endoscopies, and imaging, with one undergoing eight differential diagnoses that were ruled out through additional testing. Recalcitrant cytopenias, a history of infection, and a family history of lymphoproliferation, infection, or autoimmunity raised suspicion of an underlying IEI, leading to genetic testing. Genetic testing identified a pathogenic variant of <jats:italic>PIK3CD<\/jats:italic> in each patient, resulting in the diagnosis of APDS. Following these diagnoses, two patients underwent modifications in the management of care with the administration of intravenous immunoglobulin therapy (IVIG), the mTOR inhibitor sirolimus, or surgical procedures. These treatment modifications either improved or resolved the cytopenias. The third patient showed improvement in immune thrombocytopenia with IVIG 1\u2005month prior to receiving a definitive diagnosis. Following diagnosis, follow-up genetic testing of family members led to the identification of additional cases of APDS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These cases highlight the importance of early genetic evaluation in patients with early-onset or recalcitrant cytopenias and demonstrate the challenges of differential diagnosis. In addition, these cases demonstrate beneficial changes in management and outcomes that can follow a definitive diagnosis, including the identification of targeted treatment options. Collectively, this case series supports the notion that underlying IEIs should be considered in the workup of early-onset or recalcitrant cytopenias, particularly in patients who present with a combination of hematologic and immunologic manifestations that are refractory to treatment, manifest at an unusually young age, or can be tied to family history.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1494945","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:37:29Z","timestamp":1732707449000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Early-onset or recalcitrant cytopenias as presenting manifestations of activated PI3K\u03b4 syndrome"],"prefix":"10.3389","volume":"12","author":[{"given":"Allison S.","family":"Remiker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Pedro Matias","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohith","family":"Jesudas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Superdock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Pateva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e27260","DOI":"10.1002\/pbc.27260","article-title":"Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults","volume":"65","author":"Rotz","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.pcl.2013.08.009","article-title":"Diagnosis and management of autoimmune cytopenias in childhood","volume":"60","author":"Teachey","year":"2013","journal-title":"Pediatr Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13052-024-01662-5","article-title":"Activated phosphoinositde 3-kinase (PI3Kdelta) syndrome: an Italian point of view on diagnosis and new advances in treatment","volume":"50","author":"Lougaris","year":"2024","journal-title":"Ital J Pediatr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fimmu.2018.00543","article-title":"Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase delta syndrome: the European society for immunodeficiencies-activated phosphoinositide 3-kinase delta syndrome registry","volume":"9","author":"Maccari","year":"2018","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fimmu.2018.00369","article-title":"Activated PI3 kinase delta syndrome: from genetics to therapy","volume":"9","author":"Michalovich","year":"2018","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"702872","DOI":"10.3389\/fped.2021.702872","article-title":"Disorders related to PI3Kdelta hyperactivation: characterizing the clinical and immunological features of activated PI3-kinase delta syndromes","volume":"9","author":"Redenbaugh","year":"2021","journal-title":"Front Pediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.gendis.2019.09.015","article-title":"An updated review on activated PI3 kinase delta syndrome (APDS)","volume":"7","author":"Singh","year":"2020","journal-title":"Genes Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1084\/jem.20141759","article-title":"Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K","volume":"211","author":"Lucas","year":"2014","journal-title":"J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","article-title":"Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: a cohort study","volume":"138","author":"Elkaim","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.jaci.2019.03.017","article-title":"PI3K pathway defects leading to immunodeficiency and immune dysregulation","volume":"143","author":"Nunes-Santos","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12016-019-08738-9","article-title":"Clinical, immunological, and genetic features in patients with activated Pi3kdelta syndrome (APDS): a systematic review","volume":"59","author":"Jamee","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s10875-018-0568-x","article-title":"Report of a Chinese cohort with activated phosphoinositide 3-kinase delta syndrome","volume":"38","author":"Wang","year":"2018","journal-title":"J Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1097\/MPH.0000000000001328","article-title":"Activated phosphoinositide 3 kinase delta syndrome (APDS): a primary immunodeficiency mimicking lymphoma","volume":"41","author":"Baleydier","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"702546","DOI":"10.3389\/fped.2021.702546","article-title":"Case report: Hodgkin lymphoma and refractory systemic lupus erythematosus unveil activated phosphoinositide 3-kinase-delta syndrome 2 in an adult patient","volume":"9","author":"Conti","year":"2021","journal-title":"Front Pediatr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"703853","DOI":"10.3389\/fped.2021.703853","article-title":"Case report: EBV chronic infection and lymphoproliferation in four APDS patients: the challenge of proper characterization, therapy, and follow-up","volume":"9","author":"Rivalta","year":"2021","journal-title":"Front Pediatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"813261","DOI":"10.3389\/fimmu.2021.813261","article-title":"Case report: first occurrence of plasmablastic lymphoma in activated phosphoinositide 3-kinase delta syndrome","volume":"12","author":"Yin","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"855445","DOI":"10.3389\/fped.2022.855445","article-title":"Beyond infections: new warning signs for inborn errors of immunity in children","volume":"10","author":"Costagliola","year":"2022","journal-title":"Front Pediatr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3389\/fimmu.2019.00586","article-title":"Primary and secondary immunodeficiency diseases in oncohaematology: warning signs, diagnosis, and management","volume":"10","author":"Sanchez-Ramon","year":"2019","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.3390\/jcm12103401","article-title":"Extended list of warning signs in qualification to diagnosis and treatment of inborn errors of immunity in children and young adults","volume":"12","author":"Dabrowska","year":"2023","journal-title":"J Clin Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2018-11-887141","article-title":"Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes","volume":"134","author":"Hadjadj","year":"2019","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"869033","DOI":"10.3389\/fimmu.2022.869033","article-title":"Underlying inborn errors of immunity in patients with Evans syndrome and multilineage cytopenias: a single-centre analysis","volume":"13","author":"Miano","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fped.2019.00304","article-title":"Evans syndrome in childhood: long term follow-up and the evolution in primary immunodeficiency or rheumatological disease","volume":"7","author":"Rivalta","year":"2019","journal-title":"Front Pediatr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jaci.2016.12.978","article-title":"Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies","volume":"140","author":"Fischer","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3389\/fimmu.2017.02005","article-title":"Epstein-Barr virus susceptibility in activated PI3Kdelta syndrome (APDS) immunodeficiency","volume":"8","author":"Carpier","year":"2017","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"906540","DOI":"10.3389\/fimmu.2022.906540","article-title":"Global expansion of Jeffrey\u2019s insights: Jeffrey Modell Foundation\u2019s genetic sequencing program for primary immunodeficiency","volume":"13","author":"Quinn","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s10875-023-01626-0","article-title":"Modulating the PI3K signalling pathway in activated PI3K delta syndrome: a clinical perspective","volume":"44","author":"Berglund","year":"2023","journal-title":"J Clin Immunol"},{"key":"B29","volume-title":"Joenja [Package Insert]","year":"2023"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood.2022015506","article-title":"Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study","volume":"140","author":"Albert","year":"2022","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jaci.2021.04.036","article-title":"International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome","volume":"149","author":"Dimitrova","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaci.2023.06.015","article-title":"Activated phosphoinositide 3-kinase delta syndrome: update from the ESID registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity","volume":"152","author":"Maccari","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/MPH.0000000000002214","article-title":"Autoimmune cytopenia as an early and initial presenting manifestation in activated PI3 kinase delta syndrome: case report and review","volume":"43","author":"Schworer","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e32816","DOI":"10.1097\/MD.0000000000032816","article-title":"Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase delta syndrome: case report and literature review","volume":"102","author":"Yang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clim.2009.05.020","article-title":"Refined characterization and reference values of the pediatric T- and B-cell compartments","volume":"133","author":"van Gent","year":"2009","journal-title":"Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2249.2010.04206.x","article-title":"Reference values for B cell subpopulations from infancy to adulthood","volume":"162","author":"Morbach","year":"2010","journal-title":"Clin Exp Immunol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1494945\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:37:32Z","timestamp":1732707452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1494945\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":36,"alternative-id":["10.3389\/fped.2024.1494945"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1494945","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"article-number":"1494945"}}